Evidence map›Paper›PMID 32070049›Full record

ArticleInternational journal of molecular sciences2020

CharXgen-Activated Bamboo Charcoal Encapsulated in Sodium Alginate Microsphere as the Absorbent of Uremic Toxins to Retard Kidney Function Deterioration.

Cheng-Jui Lin, Chiao-Yin Sun, Chih-Jen Wu, Chau-Chung Wu, Vincent Wu, Feng-Huei Lin

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Cheng-Jui LinDivision of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei 10449, Taiwan.
Chiao-Yin SunDivision of Nephrology, Department of Internal Medicine, Keelung Chang Gung Memorial Hospital, 20401 Keelung, Taiwan.
Chih-Jen WuDivision of Nephrology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei 10449, Taiwan.
Chau-Chung WuDivision of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, 10048 Taipei, Taiwan.
Vincent WuDivision of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, 10048 Taipei, Taiwan.
Feng-Huei LinInstitute of Biomedical Engineering, National Taiwan University, 10048 Taipei, Taiwan.
Mackay Memorial Hospital · TWKeelung Chang Gung Memorial Hospital · TWNational Taiwan University · TWNational Taiwan University Hospital · TW

Funding

Mackay Memorial Hospital MMH-106-30 and MMH-107-31
6 · The paper itself

Abstract

Indoxyl sulphate (IS) and p-cresyl sulphate (PCS) are two protein bound uraemic toxins accumulated in chronic kidney disease (CKD) and associated with adverse outcomes. The purpose of this study isto evaluate the effect of the new activated charcoal, CharXgen, on renal function protection and lowering serum uraemic toxins in CKD animal model. The physical character of CharXgen was analyzed before and after activation procedure by Scanning Electron Microscope (SEM) and X-ray diffractometer (XRD). The effect of CharXgen on biochemistry and lowering uremic toxins was evaluated by in vitro binding assay and CKD animal model. CharXgen have high interior surface area analyzed by SEM and XRD and have been produced from local bamboo after an activation process. CharXgen was able to effectively absorb IS, p-cresol and phosphate in an in vitro gastrointestinal tract simulation study. The animal study showed that CharXgen did not cause intestine blackening. Serum albuminand liver function did not change after feeding with CharXgen. Moreover, renal function was improved in CKD rats fed with CharXgen as compared to the CKD group, and there were no significant differences in the CKD and the CKD + AST-120 groups. Serum IS and PCS were higher in the CKD group and lower in rats treated with CharXgen and AST-120. In rats treated with CharXgen, Fibroblast growth factor 23 was significantly decreased as compared to the CKD group. This change cannot be found in rats fed with AST-120.It indicates that CharXgen is a new safe and non-toxic activated charcoal having potential in attenuating renal function deterioration and lowering protein-bound uraemic toxins. Whether the introduction of this new charcoal could further have renal protection in CKD patients will need to be investigated further.

Indexed as

AlginatesAnimalsCarbonCell LineCharcoalCresolsDisease Models, AnimalHumansIndicanMicroscopy, Electron, ScanningMicrospheresOxidesRatsRenal Insufficiency, ChronicSasaSulfuric Acid Esters4-cresol sulfateAlginatesAST 120CarbonCharcoalCresolsIndicanOxidesSulfuric Acid EstersToxins, BiologicalBamboo charcoalCharXgenChronic kidney diseaseFibroblast growth factor 23Indoxyl sulphateP-cresolsulphate

Identifiers

PMID32070049
PMCPMC7072866
OpenAlexW3006661443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.